Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Completed · Phase 3 · Has a placebo group

Conditions studied: Obstructive Hypertrophic Cardiomyopathy (oHCM)

In brief

The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.

Key facts

Study ID
NCT05186818
Run by
Cytokinetics
People needed
282
Starts
2022-02-01
Expected to finish
2023-12-18
Last updated by the study team
2026-03-03

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.